VIMKUNYA™ is an FDA- and EMA-approved, single-dose, recombinant chikungunya vaccine for individuals 12+ years, demonstrating high immunogenicity and tolerability. It’s stored refrigerated, shaken before use, and administered IM. Most adverse effects are mild and transient, with rare serious events that require standard post-vaccination monitoring.

VIMKUNYA™ is used to help protect individuals aged 12 years and older against chikungunya virus infection — a mosquito-borne illness that can cause fever, joint pain, fatigue, rash, and long-term arthritis-like symptoms.

It is especially recommended for:

  • Travelers visiting regions where chikungunya outbreaks are common

  • People living in or moving to endemic areas (e.g., parts of Africa, Asia, the Caribbean, Central and South America)

  • Laboratory and field workers who may be exposed to the virus

The vaccine helps the body build immunity without causing the disease and provides a single-dose option for rapid protection.

See prescribing info

Mode of action

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus vitae tempor nulla.

 See Encepur® in action in this short video.

  • Seroresponse rate (neutralizing antibodies):

  • At 6 months post-vaccination: antibody levels remain high (85% in younger adults; 76% in older adults) CDC+1U.S. Food and Drug Administration+1.

  • Approved through accelerated FDA (Feb 2025) and MHRA/EMA processes, based on immunogenicity data from Phase III (3,500+ participants) Wikipedia+1Vaccine Advisor+1.

  • No real-world effectiveness studies yet—approval based on neutralizing antibody as surrogate endpoint

35

Lorem ipsum dolor sit amet,

50+

Lorem ipsum dolor sit amet,

100%

Lorem ipsum dolor sit amet,

Order Vimkunya®▼ Chikungunya vaccine (recombinant, adsorbed)

PIP CODE 4362067

Please note: Prices shown do not include any additional discounts and delivery charges you may be eligible for.

How To Store

  • Refrigerate at 2–8 °C; keep in original carton, protected from light vimkunyahcp.com+15U.S. Food and Drug Administration+15European Commission+15.

  • Do not freeze.

  • After removal, can be stored at room temperature (≤ 25 °C) for up to 2 h (US) or 4 h (EU/UK) before use

Dosage & Administration

0.8 mL (≈ 40 µg VLPs + aluminium adjuvant)

to create a uniform suspension (white, cloudy) before injection

do not give IV, ID, or SC

Contraindications

  • History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine

  • Pregnancy and immune‑compromised individuals: use with caution; protective efficacy may be reduced; monitor closely U.S. Food and Drug AdministrationEuropean Commission.

  • Postpone vaccination during acute severe febrile illnesses

Side Effects

Common (≥10% in ages 12–64):

  • Injection-site pain (23.7%)

  • Fatigue (19.9%)

  • Headache (18%)

  • Myalgia (17.6%)

Side Effect

Description, lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor in

Side Effect

Description, lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor in

Vimkunya® Resources

Find out the latest updates and information on Vimkunya®.

PDF

Beratung von Patient:innen zur Chikungunya-Impfung

September 30, 2025

Download
PDF

Phase-3-Studie von Vimkunya® | Richardson et. al. (2025)

September 30, 2025

Download
Article

Virus-like Particles (VLPs) – moderne Impftechnologie mit gutem Sicherheitsprofil

September 16, 2025

Read more
Article

Vimkunya® – Ein innovativer Schutz gegen das Chikungunya-Virus

September 16, 2025

Read more
Article

Vimkunya®: Ein Totimpfstoff

September 16, 2025

Read more
Article

Chikungunya: Krankheitsmanagement – Prävention als beste Therapie

September 16, 2025

Read more

Find out more

02 July 2025

VIMKUNYA™ is an FDA- and EMA-approved, single-dose, recombinant chikungunya vaccine for individuals 12+ years, demonstrating high immunogenicity and tolerability. It’s stored refrigerated, shaken before use, and administered IM. Most adverse effects are mild and transient, with rare serious events that require standard post-vaccination monitoring.